Key facts
- It has raised $28.2M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Addor Capital, GL Ventures, Zijin Hi-Tech Venture Capital, Nanjing Innovation Capital Group, Qingdao Haier Venture Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Miaoshun Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Miaoshun Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Miaoshun Biotechnology
Provider of cell and gene therapy platform intended to empower the innovative drug development industry. The company's products and services include cell separation service platforms, cell culture platforms and drug discovery platforms, permitting clients to enhance innovative drug discovery and development capabilities.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2014
- Employees
- 10
- Website
- miles-bio.com/
- Ownership
- Privately Held (backing)
Miaoshun Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Miaoshun Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Miaoshun Biotechnology in its N-PORT filings yet. We sweep new filings monthly.